Consolidated Statements of Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Shares	Common Shares Subscribed	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Private Placement Cowen and Company, LLC	Private Placement Cowen and Company, LLC Common Shares	Private Placement Cowen and Company, LLC Additional Paid-in Capital	Private Placement Roivant Sciences, Ltd.	Private Placement Roivant Sciences, Ltd. Common Shares	Private Placement Roivant Sciences, Ltd. Additional Paid-in Capital	Private Placement NovaQuest	Private Placement NovaQuest Common Shares	Private Placement NovaQuest Additional Paid-in Capital	Public Equity Offering	Public Equity Offering Common Shares	Public Equity Offering Additional Paid-in Capital
Beginning balance (in shares) at Mar. 31, 2017		60,275,757
Beginning balance at Mar. 31, 2017	$ 166,776	$ 1	$ (1)	$ 251,733	$ 140	$ (85,097)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued to settle the Takeda warranty liability	$ 58	$ 0		58
Shares issued to settle the Takeda warrant liability (in shares)	4,432	4,432
Share-based compensation expense	$ 10,587	$ 0		10,587
Share-based compensation expense (in shares)		564,111
Capital contribution from former majority shareholder — share-based compensation	996			996
Foreign currency translation adjustment	(116)				(116)
Stock option exercises	$ 36	$ 0		36
Stock option exercises (in shares)	15,195	15,195
Shares issued													$ 1,857	$ 0	$ 1,857
Shares issued (in shares)														138,361
Warrants issued with debt financing	$ 789			789
Settlement of former majority shareholder common shares subscribed	1		1
Net Loss	(143,255)					(143,255)
Ending balance (in shares) at Mar. 31, 2018		60,997,856
Ending balance at Mar. 31, 2018	37,729	$ 1	0	266,178	24	(228,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	18,067	$ 0		18,067
Share-based compensation expense (in shares)		0
Capital contribution from former majority shareholder — share-based compensation	629			629
Foreign currency translation adjustment	$ 483				483
Stock option exercises (in shares)	154,494
Shares issued							$ 84,052	$ 0	$ 84,052	$ 22,500	$ 0	$ 22,500	$ 37,982	$ 0	$ 37,982	$ 74,391	$ 0	$ 74,391
Shares issued (in shares)								3,970,129			1,110,015			2,286,284			3,533,399
Net Loss	$ (273,551)					(273,551)
Capital contribution from former majority shareholder	752			752
Issuance of shares upon exercise of stock options and vesting of PSUs and RSUs (in shares)		159,807
Issuance of shares upon exercise of stock options and vesting of PSUs and RSUs	$ 1,300	$ 0		1,300
Ending balance (in shares) at Mar. 31, 2019	72,057,490	72,057,490
Ending balance at Mar. 31, 2019	$ 4,334	$ 1	0	505,851	507	(502,025)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	40,102	$ 0		40,102
Share-based compensation expense (in shares)		0
Capital contribution from former majority shareholder — share-based compensation	149			149
Foreign currency translation adjustment	$ (2,153)				(2,153)
Stock option exercises (in shares)	124,097
Shares issued							$ 2,546	$ 0	$ 2,546							$ 134,458	$ 1	$ 134,457
Shares issued (in shares)								106,494									17,424,243
Net Loss	$ (288,989)					(288,989)
Capital contribution from former majority shareholder	334			334
Issuance of shares upon exercise of stock options and vesting of PSUs and RSUs (in shares)		245,771
Issuance of shares upon exercise of stock options and vesting of PSUs and RSUs	$ 942	$ 0		942
Ending balance (in shares) at Mar. 31, 2020	89,833,998	89,833,998
Ending balance at Mar. 31, 2020	$ (108,277)	$ 2	$ 0	$ 684,381	$ (1,646)	$ (791,014)